Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rev-CHOP for First-Line Treatment of AITL in Elderly Patients
NCT01553786Phase 2Completed
- Sponsor
- LYSARC
- Start
- Nov 2011
- Primary completion
- Mar 2018
- Countries
- 2
01
Overview
A Phase 2 trial of lenalidomide in angioimmunoblastic T-cell lymphoma (AITL), sponsored by LYSARC. Started Nov 2011; status: completed.
02
Drugs
lenalidomide
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT01553786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553786.